{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:07:25Z","timestamp":1787843245739,"version":"build-2784847793"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL007088"],"award-info":[{"award-number":["T32HL007088"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL007088"],"award-info":[{"award-number":["T32HL007088"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL007088"],"award-info":[{"award-number":["T32HL007088"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL134952"],"award-info":[{"award-number":["R01HL134952"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02568-3","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T06:22:23Z","timestamp":1765866143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A proteogenomic gene signature defines prognostic subgroups highlighting PI3K\/AKT\/mTOR signaling pathway as a therapeutic vulnerability in myeloid malignancies"],"prefix":"10.1186","volume":"24","author":[{"given":"Fan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A. C.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Letson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Brakhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Fulbright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Di Paola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"issue":"1","key":"2568_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-020-00908-z","volume":"13","author":"M Yi","year":"2020","unstructured":"Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13(1):72.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2568_CR2","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","volume":"28","author":"AGX Zeng","year":"2022","unstructured":"Zeng AGX, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med. 2022;28(6):1212\u201323.","journal-title":"Nat Med"},{"key":"2568_CR3","doi-asserted-by":"publisher","first-page":"683401","DOI":"10.3389\/fimmu.2021.683401","volume":"12","author":"DAC Fisher","year":"2021","unstructured":"Fisher DAC, Fowles JS, Zhou A, Oh ST. Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms. Front Immunol. 2021;12:683401.","journal-title":"Front Immunol"},{"issue":"1","key":"2568_CR4","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1038\/s41467-022-32928-3","volume":"13","author":"MF Rahman","year":"2022","unstructured":"Rahman MF, Yang Y, Le BT, Dutta A, Posyniak J, Faughnan P, Sayem MA, Aguilera NS, Mohi G. Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm. Nat Commun. 2022;13(1):5347.","journal-title":"Nat Commun"},{"issue":"5","key":"2568_CR5","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1182\/bloodadvances.2023011338","volume":"8","author":"S Rai","year":"2024","unstructured":"Rai S, Zhang Y, Grockowiak E, Kimmerlin Q, Hansen N, Stoll CB, Usart M, Luque Paz D, Hao-Shen H, Zhu Y, et al. IL-1beta promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells. Blood Adv. 2024;8(5):1234\u201349.","journal-title":"Blood Adv"},{"issue":"1","key":"2568_CR6","first-page":"27","volume":"4","author":"A Lasry","year":"2023","unstructured":"Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker CJ, Sun Z, Witkowski MT, Tikhonova AN, Guillamot-Ruano M, et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023;4(1):27\u201342.","journal-title":"Nat Cancer"},{"issue":"13","key":"2568_CR7","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","volume":"18","author":"A Carey","year":"2017","unstructured":"Carey A, Edwards DKt, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, et al. Identification of Interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 2017;18(13):3204\u201318.","journal-title":"Cell Rep"},{"issue":"8","key":"2568_CR8","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","volume":"33","author":"DAC Fisher","year":"2019","unstructured":"Fisher DAC, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, Allen MJ, Malkova ON, Oh ST. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFkappaB signaling. Leukemia. 2019;33(8):1978\u201395.","journal-title":"Leukemia"},{"issue":"9","key":"2568_CR9","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1038\/leu.2016.377","volume":"31","author":"DAC Fisher","year":"2017","unstructured":"Fisher DAC, Malkova O, Engle EK, Miner CA, Fulbright MC, Behbehani GK, Collins TB, Bandyopadhyay S, Zhou A, Nolan GP, et al. Mass cytometry analysis reveals hyperactive NF kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia. 2017;31(9):1962\u201374.","journal-title":"Leukemia"},{"issue":"15","key":"2568_CR10","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-23-3468","volume":"30","author":"D Tran","year":"2024","unstructured":"Tran D, Beeler JS, Liu J, Wiley B, Chan ICC, Xin Z, Kramer MH, Batchi-Bouyou AL, Zong X, Walter MJ, et al. Plasma proteomic signature predicts myeloid neoplasm risk. Clin Cancer Res. 2024;30(15):3220\u20138.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2568_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387\u201397.","journal-title":"Cancer Cell"},{"issue":"2","key":"2568_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","volume":"70","author":"O Abdel-Wahab","year":"2010","unstructured":"Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70(2):447\u201352.","journal-title":"Cancer Res"},{"issue":"3","key":"2568_CR13","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3349\/ymj.2012.53.3.530","volume":"53","author":"Y Kim","year":"2012","unstructured":"Kim Y, Yoon S, Kim SJ, Kim JS, Cheong JW, Min YH. Myeloperoxidase expression in acute myeloid leukemia helps identifying patients to benefit from transplant. Yonsei Med J. 2012;53(3):530\u20136.","journal-title":"Yonsei Med J"},{"key":"2568_CR14","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Trevino V, Shen H, Laird PW, Levine DA, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"issue":"5","key":"2568_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"key":"2568_CR16","doi-asserted-by":"crossref","unstructured":"He F, Laranjeira AB, Kong T, Lin S, Ashworth KJ, Liu A, Lasky NM, Fisher DA, Cox MJ, Fulbright MC et al. Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms. J Clin Invest 2024, 134(3).","DOI":"10.1172\/JCI172256"},{"key":"2568_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.exphem.2023.09.002","volume":"128","author":"M Burocziova","year":"2023","unstructured":"Burocziova M, Grusanovic S, Vanickova K, Kosanovic S, Alberich-Jorda M. Chronic inflammation promotes cancer progression as a second hit. Exp Hematol. 2023;128:30\u20137.","journal-title":"Exp Hematol"},{"issue":"1","key":"2568_CR18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41467-024-55643-7","volume":"16","author":"T Kong","year":"2025","unstructured":"Kong T, Laranjeira ABA, Letson CT, Yu L, Lin S, Fowles JS, Fisher DAC, Ng S, Yang W, He F, et al. RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia. Nat Commun. 2025;16(1):492.","journal-title":"Nat Commun"},{"issue":"11","key":"2568_CR19","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.leukres.2013.07.032","volume":"37","author":"V Shivarov","year":"2013","unstructured":"Shivarov V, Gueorguieva R, Stoimenov A, Tiu R. DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients. Leuk Res. 2013;37(11):1445\u201350.","journal-title":"Leuk Res"},{"issue":"14","key":"2568_CR20","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1016\/j.cell.2024.05.003","volume":"187","author":"H Wang","year":"2024","unstructured":"Wang H, Divaris K, Pan B, Li X, Lim JH, Saha G, Barovic M, Giannakou D, Korostoff JM, Bing Y, et al. Clonal hematopoiesis driven by mutated DNMT3A promotes inflammatory bone loss. Cell. 2024;187(14):3690\u2013711. e3619.","journal-title":"Cell"},{"issue":"12","key":"2568_CR21","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.3324\/haematol.2012.064667","volume":"97","author":"PA Greif","year":"2012","unstructured":"Greif PA, Konstandin NP, Metzeler KH, Herold T, Pasalic Z, Ksienzyk B, Dufour A, Schneider F, Schneider S, Kakadia PM, et al. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica. 2012;97(12):1909\u201315.","journal-title":"Haematologica"},{"issue":"7","key":"2568_CR22","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1038\/bcj.2014.47","volume":"4","author":"H Matsuo","year":"2014","unstructured":"Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe K, Kodama K, Tokumasu M, Itoh H, et al. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese pediatric Leukemia\/Lymphoma study group. Blood Cancer J. 2014;4(7):e226.","journal-title":"Blood Cancer J"},{"key":"2568_CR23","doi-asserted-by":"crossref","unstructured":"Maeser D, Gruener RF, Huang RS. OncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform 2021, 22(6).","DOI":"10.1093\/bib\/bbab260"},{"issue":"1","key":"2568_CR24","first-page":"108","volume":"4","author":"T Kong","year":"2023","unstructured":"Kong T, Laranjeira ABA, Yang K, Fisher DAC, Yu L, De La Poittevin L, Wang AZ, Ruzinova MB, Fowles JS, Fulbright MC, et al. DUSP6 mediates resistance to JAK2 Inhibition and drives leukemic progression. Nat Cancer. 2023;4(1):108\u201327.","journal-title":"Nat Cancer"},{"issue":"5","key":"2568_CR25","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.cell.2011.07.032","volume":"146","author":"SM Sykes","year":"2011","unstructured":"Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, et al. AKT\/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 2011;146(5):697\u2013708.","journal-title":"Cell"},{"key":"2568_CR26","doi-asserted-by":"publisher","first-page":"779899","DOI":"10.3389\/fphar.2021.779899","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Lu J, Wang J, Deng P, Meng C, Tang H. Inflammatory cytokines and risk of ischemic stroke: A Mendelian randomization study. Front Pharmacol. 2021;12:779899.","journal-title":"Front Pharmacol"},{"issue":"16","key":"2568_CR27","doi-asserted-by":"publisher","first-page":"e029003","DOI":"10.1161\/JAHA.122.029003","volume":"12","author":"X Wang","year":"2023","unstructured":"Wang X, Huang T, Jia J. Proteome-Wide Mendelian randomization analysis identified potential drug targets for atrial fibrillation. J Am Heart Assoc. 2023;12(16):e029003.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2568_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12920-024-01826-6","volume":"17","author":"L Lin","year":"2024","unstructured":"Lin L, Yu H, Xue Y, Wang L, Zhu P. Proteome-wide Mendelian randomization investigates potential associations in heart failure and its etiology: emphasis on PCSK9. BMC Med Genomics. 2024;17(1):59.","journal-title":"BMC Med Genomics"},{"issue":"12","key":"2568_CR29","first-page":"5826","volume":"15","author":"P Ke","year":"2023","unstructured":"Ke P, Zhu Q, Xu T, Yang X, Wang Y, Qiu H, Wu D, Bao X, Chen S. Identification and validation of a 7-genes prognostic signature for adult acute myeloid leukemia based on aging-related genes. Aging. 2023;15(12):5826\u201353.","journal-title":"Aging"},{"key":"2568_CR30","doi-asserted-by":"crossref","unstructured":"Zhai Y, Shen H, Wei H. A comprehensive Metabolism-Related gene signature predicts the survival of patients with acute myeloid leukemia. Genes (Basel) 2023, 15(1).","DOI":"10.3390\/genes15010063"},{"issue":"1","key":"2568_CR31","doi-asserted-by":"publisher","first-page":"9115","DOI":"10.1038\/s41598-024-59464-y","volume":"14","author":"J Wang","year":"2024","unstructured":"Wang J, Wang H, Ding Y, Jiao X, Zhu J, Zhai Z. NET-related gene signature for predicting AML prognosis. Sci Rep. 2024;14(1):9115.","journal-title":"Sci Rep"},{"key":"2568_CR32","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5550116","volume":"2021","author":"F Jiang","year":"2021","unstructured":"Jiang F, Wang XY, Wang MY, Mao Y, Miao XL, Wu CY, et al. An immune checkpoint-related gene signature for predicting survival of pediatric acute myeloid leukemia. J Oncol. 2021;2021:5550116.","journal-title":"J Oncol"},{"issue":"7","key":"2568_CR33","first-page":"4898","volume":"14","author":"X Wu","year":"2022","unstructured":"Wu X, Li S, Chen D, Zheng G, Zhang Z, Li Z, Sun X, Zhao Q, Xu J. An inflammatory response-related gene signature associated with immune status and prognosis of acute myeloid leukemia. Am J Transl Res. 2022;14(7):4898\u2013917.","journal-title":"Am J Transl Res"},{"key":"2568_CR34","doi-asserted-by":"publisher","first-page":"819128","DOI":"10.3389\/fonc.2022.819128","volume":"12","author":"Y Peng","year":"2022","unstructured":"Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway? Front Oncol. 2022;12:819128.","journal-title":"Front Oncol"},{"issue":"8015","key":"2568_CR35","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41586-024-07410-3","volume":"630","author":"Q Luo","year":"2024","unstructured":"Luo Q, Raulston EG, Prado MA, Wu X, Gritsman K, Whalen KS, Yan K, Booth CAG, Xu R, van Galen P, et al. Targetable leukaemia dependency on noncanonical PI3Kgamma signalling. Nature. 2024;630(8015):198\u2013205.","journal-title":"Nature"},{"issue":"8","key":"2568_CR36","doi-asserted-by":"publisher","first-page":"eade8222","DOI":"10.1126\/sciadv.ade8222","volume":"9","author":"K Ames","year":"2023","unstructured":"Ames K, Kaur I, Shi Y, Tong MM, Sinclair T, Hemmati S, Glushakow-Smith SG, Tein E, Gurska L, Steidl U, et al. PI3-kinase deletion promotes myelodysplasia by dysregulating autophagy in hematopoietic stem cells. Sci Adv. 2023;9(8):eade8222.","journal-title":"Sci Adv"},{"issue":"1","key":"2568_CR37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, Li B. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):425.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"2568_CR38","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","volume":"21","author":"Q Yang","year":"2015","unstructured":"Yang Q, Modi P, Newcomb T, Queva C, Gandhi V. Idelalisib: First-in-Class PI3K delta inhibitor for the treatment of chronic lymphocytic Leukemia, small lymphocytic Leukemia, and follicular lymphoma. Clin Cancer Res. 2015;21(7):1537\u201342.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2568_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(22)00200-5","volume":"23","author":"NC Richardson","year":"2022","unstructured":"Richardson NC, Kasamon Y, Pazdur R, Gormley N. The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. Lancet Oncol. 2022;23(5):563\u20136.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2568_CR40","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/bloodadvances.2023011620","volume":"8","author":"A Yacoub","year":"2024","unstructured":"Yacoub A, Borate U, Rampal RK, Ali H, Wang ES, Gerds AT, Hobbs G, Kremyanskaya M, Winton E, O\u2019Connell C, et al. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results. Blood Adv. 2024;8(6):1515\u201328.","journal-title":"Blood Adv"},{"key":"2568_CR41","doi-asserted-by":"publisher","first-page":"114498","DOI":"10.1016\/j.ejmech.2022.114498","volume":"238","author":"P Oleksak","year":"2022","unstructured":"Oleksak P, Nepovimova E, Chrienova Z, Musilek K, Patocka J, Kuca K. Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015\u20132021). Eur J Med Chem. 2022;238:114498.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"2568_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1021\/ml900028r","volume":"1","author":"SD Knight","year":"2010","unstructured":"Knight SD, Adams ND, Burgess JL, Chaudhari AM, Darcy MG, Donatelli CA, Luengo JI, Newlander KA, Parrish CA, Ridgers LH, et al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of Rapamycin. ACS Med Chem Lett. 2010;1(1):39\u201343.","journal-title":"ACS Med Chem Lett"},{"issue":"12","key":"2568_CR43","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41417-023-00675-2","volume":"30","author":"CY Tseng","year":"2023","unstructured":"Tseng CY, Fu YH, Ou DL, Lu JW, Hou HA, Lin LI. Anti-leukemia effects of omipalisib in acute myeloid leukemia: inhibition of PI3K\/AKT\/mTOR signaling and suppression of mitochondrial biogenesis. Cancer Gene Ther. 2023;30(12):1691\u2013701.","journal-title":"Cancer Gene Ther"},{"issue":"7728","key":"2568_CR44","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526\u201331.","journal-title":"Nature"},{"issue":"3","key":"2568_CR45","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/jha2.890","volume":"5","author":"S Lin","year":"2024","unstructured":"Lin S, Gao B, Xu R, Shang H, Xiong Y, Zhou J, et al. Multiple myeloma, IL6, and risk of schizophrenia: a Mendelian randomization, transcriptome, and bayesian colocalization study. EJHaem. 2024;5(3):462\u201373.","journal-title":"EJHaem"},{"issue":"7982","key":"2568_CR46","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun BB, Chiou J, Traylor M, Benner C, Hsu YH, Richardson TG, Surendran P, Mahajan A, Robins C, Vasquez-Grinnell SG, et al. Plasma proteomic associations with genetics and health in the UK biobank. Nature. 2023;622(7982):329\u201338.","journal-title":"Nature"},{"issue":"9","key":"2568_CR47","doi-asserted-by":"publisher","first-page":"e1009440","DOI":"10.1371\/journal.pgen.1009440","volume":"17","author":"C Wallace","year":"2021","unstructured":"Wallace C. A more accurate method for colocalisation analysis allowing for multiple causal variants. PLoS Genet. 2021;17(9):e1009440.","journal-title":"PLoS Genet"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02568-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02568-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02568-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:06:17Z","timestamp":1769605577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-025-02568-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2568"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02568-3","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All research complies with all relevant ethical regulations. Patient and healthy donor control peripheral blood (PB) or bone marrow (BM) samples were obtained according to a protocol approved by the Washington University Human Studies Committee (WU no. 01-1014). All patients previously provided consent to have samples banked and were not newly recruited for this study. All in vivo procedures were conducted in accordance with the Institutional Animal Care and Use Committee (IACUC) of Washington University (no. 20\u20130463). Mice were handled according to standard care procedures compliant with Washington University Department of Comparative Medicine facility including: bedding, cage change interval, light cycle, temperature, humidity, food type, water, and caging. The maximal disease burden denoted by the ethics committee\/institutional review board (e.g., moribund and sluggish appearance, hunched and with ruffled coats, harboring visible lesions) was not exceeded. Animals were humanely euthanized upon immobility or appearance with signs of distress.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable because no individual data was used in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.T.O. has served as a consultant for Kartos Therapeutics, CTI BioPharma, Celgene\/Bristol Myers Squibb, Disc Medicine, Blueprint Medicines, PharmaEssentia, Constellation, Geron, Abbvie, Sierra Oncology, and Incyte. All other authors disclose no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}